When was Massive Bio founded?

Massive Bio was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is Massive Bio located?

Massive Bio is headquartered in New York City, United States.

How many employees does Massive Bio have?

As of Jul 31, 2026, the latest employee count at Massive Bio is 98.

Is Massive Bio a funded company?

Massive Bio is a funded company, having raised a total of $15.6M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 26, 2016.

When was the latest funding round of Massive Bio?

Massive Bio's latest funding was a $***** Series B round on Jun 02, 2022, with participation from 3 investors.

Where does Massive Bio rank among its competitors?

Massive Bio ranks 11th amongst 304 active competitors, of which 54 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Verily, which secured $300M in Mar, 2026.

Who are the top competitors of Massive Bio?

Massive Bio's top competitors include Medidata, Verily and IQVIA. Among them, Verily secured the most recent funding round in March, 2026.

Massive Bio - 2026 Company Profile, Team, Funding & Competitors

Massive Bio is a series B company based in New York City (United States), founded in 2014 by Selin Kurnaz. It operates as a Provider of AI-based clinical trial management tool. Massive Bio has raised $15.6M in funding from Revo Capital. The company has 304 active competitors, including 54 funded and 42 that have exited. Its top competitors include companies like Medidata, Verily and IQVIA.

Company Details

Provider of AI-based clinical trial management tool. The platform is offering full-stack engineering technology for real-time patient identification, clinical trial matching tools, continuous monitoring, and clinical coordination support for the management of clinical trials.

Website: massivebio.com
Social
Email ID: *****@massbio.io
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2014

Location

New York City, United States

Stage

Series B

Total Funding

$15.6M in 4 rounds

Latest Funding Round

Series B, Jun 02, 2022, $*****

Investors

Revo Capital & 9 more

Ranked

11^th among 304 active competitors

Employee Count

98 as on Jul 31, 2026

Similar Companies

Medidata & 347 more

View Massive Bio's full profile

Massive Bio has raised a total funding of $15.6M over 4 rounds. Its first funding round was on Sep 26, 2016. Its latest funding round was a Series B round on Jun 02, 2022 for $*****. 3 investors participated in its latest round. Massive Bio has 9 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Massive Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 02, 2022	4711784	Series B	9195403	6962276	2077211	7369284
Nov 03, 2020	5880961	Series A	8645071	7744214	6383976	ImpactAssets
May 02, 2019	6081520	Seed	5010275	6345082	4845407	7468948

Access funding benchmarks and valuations. Sign up today!

View details of Massive Bio's funding rounds and investors

The founders of Massive Bio is Selin Kurnaz.

Here are the details of Massive Bio's key team members:

Selin Kurnaz: Co-Founder & CEO of Massive Bio and founder of 5 other companies, including Cervical Cancer, Massive Bio and B-Cell Lymphoma.
Contact Info: 1 email address

View details of Massive Bio's Founder profiles and Board Members

Massive Bio's employee count trend

Massive Bio has 98 employees as of Jul 26. Here is Massive Bio's employee count trend over the years:

Uncover Massive Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Massive Bio include Medidata, Verily and IQVIA. Here is the list of Top 10 competitors of Massive Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Medidata 1999, New York City (United States), Acquired	AI-based clinical trial management software for researchers	$41.5M	Insight Partners, TFS & 11 others	86/100
2nd	Verily 2015, Dallas (United States), Series D	A data platform and technology company purpose-built to power AI-enabled precision health	$2.8B	Silver Lake, Temasek & 9 others	82/100
3rd	IQVIA 1982, Durham (United States), Public	Provider of clinical research and commercialization solutions for healthcare	$1.74M	Leonard Green and Partners, Aisling Capital ... & 12 others	80/100
4th	Tempus 2015, Chicago (United States), Public	Developer of genomic testing and artificial intelligence tools for medicine	$1.05B	T. Rowe Price, New Enterprise Associates ... & 11 others	77/100
5th	Signant Health 2000, Plymouth Meeting (United States), Acquired	Provider of a software solution for clinical trial management	$3.4M	Harvest Partners, 3i Group & 4 others	72/100
6th	Science 37 2014, Los Angeles (United States), Acquired	Provider of a suite solution for clinical trials for researchers	$106M	Redmile Group, Lux Capital & 12 others	70/100
7th	TriNetX 2013, Cambridge (United States), Acquired	Provider of clinical trial management software for researchers and professionals	$102M	Merck Global Health Innovation Fund, MPM Capital ... & 6 others	66/100
8th	BrightInsight 2017, San Jose (United States), Series C	Provider of digital health solutions for clinical trials	$179M	New Leaf Venture Partners, General Catalyst ... & 8 others	64/100
9th	Wcg Clinical 2012, Princeton (United States), Acquired	CRO offering regulatory and ethical review services for clinical research	-	Ares Capital Corporation, Annox Capital & 6 others	64/100
10th	Viz.ai 2016, San Francisco (United States), Series D	Developer of an AI-powered platform for care coordination and disease detection	$252M	Insight Partners, Tiger Global Management ... & 17 others	64/100
11th	Massive Bio 2014, New York City (United States), Series B	Provider of AI-based clinical trial management tool	$15.6M	Philips HealthWorks, e2vc & 8 others	59/100